Addressing an Evolving Drug Safety Landscape - Moving from passive to active pharmacovigilance


Pharma and Biotech organizations are facing growing challenges from the rapidly developing pharmacovigilance landscape and demands for the collection of more relevant safety data. These factors, combined with the pressure of cost containment, demand that life science organisations consider different approaches to the traditional, largely manual PV processes. A risk-based processing approach introduces a highly effective and efficient process to manage drug safety, ensuring quality data is collected across the portfolio, from newly launched to established products.

Request More Information

To find out more or request a demo fill in the details below:

By submitting your information, you are consenting to receive communications from MyMeds&Me. You may at any time 'opt out' of receiving these marketing communications by emailing

Keep informed

For expert insight and updates from the MyMeds&Me team.

We respect your privacy and we will only use your email address for newsletters and company updates